Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Want to cut your energy bills? Here’s how five experts are doing it 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
BOSTON, March 31, 2016 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2nd Annual Immuno-Oncology Summit on Thursday, April 7th, 2016 at 9:35 a.m. ET. The conference is being held at the Boston Harbor Hotel in Boston, MA.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Contact: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 617-259-1987 [email protected] David Pitts Argot Partners 212-600-1902 [email protected]
